Ohad Hammer

The Long Case for Pfizer

Very nice interview, clear and simple.
imo, Berkowitz is right on the money.
The pharma industry is facing a patent cliff, but it doesn't mean companies like Pfizer will actually fall off a cliff. It will still generate plenty of cash and will be able to utilize its huge global footprint.
Can't say I follow every investigational agent in the company's pipeline, but it seems to have quite a few interesting drugs, particularly in the pain/inflammation area.
I am still a little bit worried about their oncology pipeline, especially the lack of antibody based drugs. They do seem to have a deep and broad small molecule pipeline, but most of it is early stage. The Wyeth deal doesn't help a lot on the oncology front, although Wyeth has a very interesting conjugate with strong data in NHL. For some reason, the company is not too public about it.

Ohad Hammer